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In Parkinson’s disease, one of the most troublesome dilemmas is the treatment of levodopa-induced dyskinesia. After a few years,
chronic treatment with levodopa is associated with the development of dyskinesias. Strategies to delay or to reduce dyskinesias are
based on the change of levodopa dosing or the early use of dopamine agonists. Dopamine agonists with diﬀerent pharmacological
proﬁle are available. Our paper was aimed to analyse the clinical impact and the management of dyskinesias with dopamine
agonists.
1.Introduction
Four decades after its introduction, levodopa remains the
most eﬀective agent to improve motor symptoms in PD, but
chronic use is associated with the emergence of motor ﬂuc-
tuations, deﬁned as a loss of clinical beneﬁt before the next
levodopa dose (wearing oﬀ), abnormal involuntary move-
ments (dystonia, chorea, and athetosis—collectively referred
to as dyskinesia) [1, 2], and nonmotor complications, as
behavioural and cognitive changes [3]. Levodopa is initially
well tolerated in most of the cases and allows a substantial
improvement of motor performances despite its erratic
pharmacokinetics [1, 4]. With the disease progression, ther-
apeutic window of levodopa narrows, and the duration of
each dose shortens. Motor ﬂuctuations usually precede dysk-
inesias [5], and it has been observed that the development of
one is a risk factor for the development of the other [5].
Although more commonly associated with levodopa,
dyskinesiascanalsooccurwithdopamineagonistmonother-
apy [6–8]. The development of dyskinesia in some patients
treatedwith dopamine agonists that haverelatively long half-
lives (ropinirole, 6h; pramipexole, 8h) or very long half-
lives (cabergoline, 68h) suggests that, to some extent, even
dopamine stimulation provided in a continuous fashion can
cause dyskinesias.
2. Epidemiology and ClinicalAspects of
Motor Complications
The three most important risk factors positively associated
with increased occurrence of dyskinesias are younger age at
disease onset [9, 10], longer disease duration [11, 12], and
longer duration of pulsatile dopaminergic treatment (typi-
cally, levodopa) [13, 14]. The ﬁrst two factors are interrelated
and almost all patients with early-onset PD [15]d e v e l o p
dyskinesias, whereas they are less frequent in patients with
late-onset PD [16]. PD patients with early disease onset have
a high probability to carry mutations for monogenic PD
forms, and therefore, early onset and genetic predisposition
are two overlapping and possibly interrelated risk factors.
Other risk factors associated with increased risk of dyskine-
sias are female gender [17, 18] and the occurrence of speciﬁc
polymorphisms for dopamine receptors or dopamine trans-
porters [19–21].
Dyskinesias more commonly appear as choreiform, but
in some cases, they may resemble dystonia, myoclonus, or2 Parkinson’s Disease
other movement disorders. Peak-dose dyskinesias are the
most common type of dyskinesia. They occur during peaks
oflevodopa-deriveddopamineinthebrain,whenthepatient
is otherwise experiencing a beneﬁcial response (the “on”
state). Peak-dose dyskinesias worsen with increases in
dopaminergic dose and lessen with its reductions. In certain
cases, dyskinesias seem to appear with a more particu-
lar pattern, as dyskinesia-improvement-dyskinesia. This is
termed diphasic dyskinesia, and it tends to occur when levo-
dopa-derived dopamine concentrations are increasing or
decreasing, whereas the clinical condition of the patient
turns “on” and “oﬀ”[ 22]. Diphasic dyskinesias are typically
displayed with large-amplitude stereotypic, rhythmic, and
repetitive movements, more often of the legs, that may be
associated with Parkinsonian features in other body regions.
In extreme cases, patients treated with levodopa can cycle
between “on” periods, which are complicated by disabling
dyskinesias, and “oﬀ” periods in which Parkinsonism is
uncontrolled and the patient is akinetic and frozen.
Motorcomplicationsoccurinabout50%ofpatientswith
PD who have been in therapy with levodopa for more than
5 years, and in almost 100% of patients with young-onset
disease[23,24].Achievinganacceptableclinicalcontrolonce
these motor ﬂuctuations have appeared is usually a relatively
simplematter,nearingtogetherthelevodopadosesoradding
medications that reduce “oﬀ” time. However, when a patient
develops peak-dose dyskinesias too, it becomes diﬃcult to
smooth the clinical response. Although for many patients,
dyskinesias are not disabling, they create a barrier to ade-
quatetreatmentofﬂuctuationsandParkinsoniansymptoms.
3.Pathophysiology ofDyskinesias
A primary condition in LID pathophysiology is the presence
of dopaminergic cell loss in substantia nigra [25–27]. The
nonappearance of dyskinesia in normal humans chronically
treated with levodopa (i.e., mistaken diagnosis [28]) and its
rapid emergence in PD patients either with late diagnosis
or a young onset, where denervation is high at diagnosis
[15, 29, 30], heavily support this theory. Moreover, the prog-
ression of nigral denervation seems to be closely related with
the lowering of the dyskinesia onset threshold in MPTP-
exposed primates [31]. Nonetheless, denervation cannot be
the unique factor responsible for dyskinesia, whereas not all
patients with advanced illness and extensive nigral denerva-
tion develop dyskinesia when treated with levodopa [32, 33].
Thus, a chronic dopaminergic stimulation on a denervated
substantia nigra induces a process of sensitisation such that
each following administration modiﬁes the response to sub-
sequent dopaminergic treatments. This process, called prim-
ing, increases over time of treatment the chance of eliciting
dyskinesiasand,oncedyskinesiashavebeenestablished,their
severity. The priming process, which is responsible for the
insidious evolution of dyskinesias over time of treatment, is
associated with changes in receptors for dopamine or other
neurotransmitters [34, 35]. A crucial role has been postu-
lated for both dopamine receptors and NMDA glutamate
receptors in the induction of priming; this mechanism could
be regarded as an increased responsiveness of postsynaptic
striatal dopamine receptors (mainly D1-like), which are acti-
vated in conjunction with glutamatergic inputs [1]. Dyski-
nesias are probably generated by a persistent enhancement
of the responsiveness of striatal medium-sized spiny neu-
rones to dopaminergic treatment. This is an aftermath of
dopamine depletion and is associated with overexpression of
speciﬁc components of the signal transduction machinery. If
protracted, this condition may ultimately lead to long-term
changesingeneexpression,whichwillpermanentlyaﬀectthe
function of striatal medium spiny neurones [36]. Following
priming, the development of dyskinesias largely depends
on two additional factors, the pulsatile administration of
levodopa (or another short-acting dopaminergic agent) and
the severity of dopaminergic denervation in the striatum.
The latter plays an important role in setting the threshold
required in developing dyskinesias [37].Adirect relationship
between the severity of striatal denervation and the time
requiredtodevelopdyskinesiashasbeendemonstratedinPD
patients [38] and has been indirectly conﬁrmed by the ﬁnd-
ing that patients with dopa-responsive dystonia, who have
Parkinsonism without nigrostriatal denervation, uncom-
monly develop dyskinesias [39].
InearlyPDpatients,levodopa-deriveddopamineispack-
aged into synaptic vesicles by vesicular monoamine trans-
porter 2 (VMAT-2), stored, and released in both tonic and
phasicburstsinresponsetoimpulseﬂow[40,41],inorderto
preserve dopamine receptors from levodopa plasma concen-
tration ﬂuctuations and, therefore, to maintain physiological
dopaminergic transmission [42, 43]. With the progression of
the disease, and the striatal dopaminergic cell loss, the for-
mation of dopamine from levodopa and its storage capacity
are increasingly compromised, and the response to levodopa
becomes dominated by its pharmacokinetic characteristics
and general bioavailability [4]. Thus, in advanced PD, peak
concentrations of drug in plasma become coincidental with
the expression of dyskinesia. As observed in animal models,
the continuous release of dopamine leads to improvements
in motor function and, together, to a marked reduction in
the expression of involuntary movements [44]. These studies
support the clinical ﬁndings that the continuous intravenous
or intraduodenal administration of levodopa or the contin-
uous subcutaneous or intravenous infusion of apomorphine
results in improved motor response but also with a marked
reduction of dyskinesia [45, 46].
Othermechanismsareinvolvedtoexplaintheunderlying
cause and expression of dyskinesia. Although dopamine ago-
nists when used as monotherapy in early PD are associated
to a lower incidence of dyskinesia, involuntary movements
are still observed, reﬂecting some kind of activity at the
postsynaptic dopamine receptor level, as dopamine agonists
are not dependent on the presence of presynaptic terminals.
Subtle changes in D1 and D2 receptor density as well
as the complex interaction between receptor activation and
synaptic plasticity [1] have been proposed as playing signiﬁ-
cant roles in dyskinesia induction and expression. Although
the exact molecular mechanisms of LID still remain to be
fully elucidated, exaggerated signalling of the striatal D1 [47–
49], the reduction of the modulating function of D2/D3Parkinson’s Disease 3
Table 1: Pharmacological characteristics of dopamine agonists.
Pramipexole Ropinirole Rotigotine Pergolide Bromocriptine Cabergoline Apomorphine Lisuride
D1 00 + + − 0/+ +++ −
D2 +++ +++ +++ ++++ ++ +++ ++ ++++
D3 ++++ ++++ ++++ +++ ++ ++ ++++ +++
Type Nonergot Nonergot Nonergot Ergoline Ergoline Ergoline Morphine deriv. Ergoline
Routes os os td os os os sc sc
Metabolism — Hepatic Hepatic Hepatic ? Hepatic Hepatic Hepatic
Elimin. Urine Urine Urine/fecal Urine/fecal Fecal Fecal/urine Urine/fecal Urine/fecal
Half-life (h) 8–12 5–6 5–7 27 12–14 63–69 40 min. 2
td: transdermal; sc: subcutaneous.
receptors [42, 43, 50–52], and the interaction between D2
and A2A adenosine receptors [53] have been implicated in
both rodents and primates, suggesting that a normalisation
of signalling may be beneﬁcial in the treatment of dyskinesia.
In clinical practice, postsynaptic mechanisms can be
partially explained by the dopamine agonists capability to
prime for involuntary movements. Switching from a chronic
dopamineagonistadministrationthatusuallyresultsinalow
expression and intensity of dyskinesia to an equivalent dose
of levodopa in fact immediately results in the appearance
of dramatic involuntary movements [54, 55]. These ﬁndings
suggestthatdopamineagonistsprincipallyprimefor,butless
commonly express dyskinesia. Vice versa, when considering
the expression of dyskinesia in patients with PD with a his-
tory of levodopa exposure, switching to a dopamine agonist
aftertheintroductionoflevodopa,establisheddyskinesiastill
occurred [56]. Moreover, patients receiving a combination
of levodopa and the dopamine D2/D3 agonist pramipexole
showed a level of dyskinesia that was greater than the
additive eﬀect of the individual drug [57]. Once established,
dopamine agonists produce the same pattern of dyskinesia
although its intensity is reduced, suggesting that agonists do
not express dyskinesia to the same extent as levodopa [54,
55, 58]. Both the lower priming for dyskinesia and the lower
expression of involuntary movements by dopamine agonists
may be a reﬂection of their more speciﬁc pharmacology
compared to levodopa.
4. Reducingor Delaying
ParkinsonianDyskinesias
Any type of exogenous dopaminergic stimulation in a
denervated striatum can cause dyskinesias [59], but pulsatile
stimulation produced by short-acting drugs (as typically
occurs with levodopa) particularly favours their occurrence
[60]. The expression LID is still currently used, although
levodopa is not the only drug causing dyskinesias in PD
patients[61].Basedonpublishedseries,ithasbeenestimated
that PD patients treated for less than 5 years have a 11% risk
of developing dyskinesias, those treated for 6–9 years have a
risk of 32%, whereas patients treated for more than 10 years
have a risk of 89% [13].
Levodopa, however, seems to be the most important fac-
tor in inducing dyskinesia expression in chronically treated
PD patients; therefore, it appears that the beneﬁt of initial
treatment with a dopamine agonist in lowering the incidence
of dyskinesias is related to the ability of the agonist to delay
the need for levodopa [12, 62]. Moreover, experimental data
suggest that the administration of long-acting dopamine
agonists results in signiﬁcantly less dyskinesia than does lev-
odopa [63, 64] and other short-acting agents administrated
in a pulsatile fashion [65]. However, once a long-acting
agonist is administered to animals already primed to exhibit
dyskinesias with levodopa, the resultant dyskinesias are com-
parable to those seen in the levodopa group [63]. Clinical
studies randomly assigning patients to initial treatment with
a dopamine agonist or levodopa have shown a lower risk
for dyskinesias in the groups treated with pramipexole [7],
ropinirole [8, 12], bromocriptine [66, 67], pergolide [68],
and cabergoline [6]; nevertheless, once levodopa was added,
the rate of development of dyskinesias was similar in both
groups.
One therapeutic strategy that has been tried in this sense
is to use higher doses of a dopamine agonist to reduce both
the total daily levodopa dose and its frequency [69]o rt o
gradually substitute a dopamine agonist for levodopa [70].
Unfortunately, these strategies are unsatisfactory and typ-
ically reduce dyskinesias at the expense of less control of
Parkinsonian symptoms. Indeed, the evidence that early
levodopa exposure adversely aﬀects the course of disease and
leads to disabling dyskinesias and motor ﬂuctuations consti-
tuted the rationale for the initial treatment with dopamine
agonist.
5. Different Proﬁle and Efﬁcacy of
DopamineAgonists inReducingDyskinesia
In order to create a valid alternative to levodopa, and with
the aim of eliminating its related complications, many dif-
ferent drugs acting on dopaminergic receptors have been
developed and studied during the last years. They have dif-
ferent metabolism, plasma half-life, aﬃnity to receptors
subtypes, excretion, and routes of administration (Table 1).
Moreover, these drugs have diﬀerent eﬃcacies on reducing
theincidenceofdyskinesia,improvingmotorsymptoms,and
reducing the daily levodopa dose (Table 2, Figure 1).
Initially dopamine agonists have been used as adjuvant
therapy to improve levodopa-induced complications, but4 Parkinson’s Disease
Table 2: Adjuvant therapy versus placebo.
Pramipexole Ropinirole Pergolide∗ Bromocriptine Cabergoline
Oﬀ-time reduction (h/day) −1.81 −0.93 −1.60 −1.78 −1.29
LEDD red (mg/day) −114.82 −119.81 −183.90 −52.17 −149.60
UPDRS ADL reduction (pts) −1.78
UPDRS III reduction (pts) −4.80 −1.74
Incidence of dyskinesia (OR) 2.63 3.21 4.64 2.52 1.44
∗Based on data from just one trial [71].
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Figure 1: Eﬀects of dopamine agonists on (a) reducing oﬀ time, (b)
reducing levodopa daily dose, and (c) inducing dyskinesia.
once their eﬀects on delaying the need for levodopa have
been demonstrated, they have often been prescribed before
the introduction of levodopa. Patients receiving dopamine
agonistsratherthanlevodopa asinitial monotherapy showed
areducedriskfordeveloping dyskinesias[7,8,12,62,72–76]
(Table 3).
5.1. Dopamine Agonists Monotherapy and the Risk of Dysk-
inesia. The CALM-PD trial (Comparison of the Agonist
Pramipexole versus Levodopa on Motor Complications of
Parkinson’s Disease) was a randomised controlled trial
evaluating the risk of developing dyskinesias in patients with
early PD initially treated with either pramipexole or lev-
odopa. After 24 months, pramipexole-treated patients were
receiving pramipexole plus levodopa, compared with lev-
odopa alone. A minority of pramipexole-treated patients
reached the endpoint of time to ﬁrst occurrence of wearing
oﬀ, dyskinesias, or on-oﬀ motor ﬂuctuations (27.8% versus
50.7%, P<0.001). Moreover, a signiﬁcantly lower incidence
of dyskinesias (9.9% versus 30.7%, P<0.001) also has been
demonstrated in patients in the pramipexole group. How-
ever, after a mean 6-year followup, >90% of patients were
receiving levodopa therapy regardless of their initial treat-
ment assignment. Compared to those taking pramipexole,
patients initially treated with levodopa had signiﬁcantly
moredyskinesias(20.4%versus36.8%),buttherewasnodif-
ference between groups in the incidence of disabling or
painful dyskinesias [62, 74]. Interestingly, 5 subjects taking
pramipexole developed dyskinesias before the supplemental
levodopa, and 4 of them had no prior levodopa exposure
[73]. No signiﬁcant diﬀerence in the Lang-Fahn activities of
dailylivingdyskinesiascorewasobserved(1.3versus1.1with
pramipexole, P<0.06) [7, 62, 72–74].
In a randomised, double-blind 5-year study of patients
with early PD, the risk of developing dyskinesias after initial
monotherapy with ropinirole was less than with lev-
odopabenserazide (hazard ratio (HR), 2.82 (1.78, 4.44);
P<0.001) [8]. However, many of these patients eventually
required supplemental levodopa to control the symptoms of
thedisease[8,12].Whenpatientsreceivingropinirolemono-
therapy required the addition of levodopa, the risk for
developing dyskinesias increased and then did not diﬀer sig-
niﬁcantly from that associated with levodopa alone [12]. The
use of ropinirole as monotherapy, with only later addition
oflevodopa, delayedtheonsetofdyskinesiasbyupto3years,
although it was associated with a higher incidence of neu-
ropsychiatric complications than levodopa monotherapy.
Apomorphine, a subcutaneous nonergolinic dopaminer-
gic agent, has been studied in 2 retrospective chronic mono-
therapy trials in which no oral anti-parkinsonian therapies
were permitted from the time the pump was turned on in
the morning until it was turned oﬀ in the evening [77, 78].
The mean maximum reduction of dyskinesia per patient was
64%(P<0.005),andthemeantimetoachievemaximaldys-
kinesia improvement was 12.1 months.
Lisuride, another subcutaneously administered dopam-
ine agonist, given as a continuous daytime infusion via
pump, has been utilised as a strategy for minimising dyski-
nesias in 40 patients with advanced, levodopa-responsive PDParkinson’s Disease 5
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characterised by motor ﬂuctuations and dyskinesias [109].
After4years,thelisuride-treatedpatientshadimprovedtheir
baseline dyskinesia scores (measured by AIMS) by 49% (P<
0.0001),whereasthelevodopa-treatedpatientshadworsened
their scores by 59% (P<0.0001).
5.2. Long-Acting Dopamine Agonists and the Risk of Dyskine-
sia. Inanimal-modelstudies,thelong-actingdopamineago-
nists have been demonstrated to prevent or reduce the onset
time for LIDs. In a study of monkeys with MPTP-induced
parkinsonism, small doses of subcutaneously administered
cabergoline, a D2-selective dopamine agonist with a rel-
atively long half-life, were added as adjuvant therapy to
orally administered levodopa/benserazide (100/25mg) for 1
month, showing signiﬁcantly lower dyskinesia scores (sum
for all body segments) than when levodopa/benserazide was
given alone for 1 month (P<0.01).
A report on the eﬀect of cabergoline compared to levo-
dopa showed a reduced incidence of dyskinesias [110]. Nev-
ertheless, more recently, an increased incidence of dyskinesia
and confusion in patients treated with bromocriptine was
reported [111].
5.3. Diﬀerences among Drugs in Adjuvant Therapy. Ar e c e n t
systematic meta-analysis, which performs indirect compar-
isons among three classes of drugs, including nondopamin-
ergic agents as catechol-O-methyl transferase inhibitors
(COMTIs) or monoamine oxidase type B inhibitors (MAO-
BIs), used as add-on (adjuvant) treatment to levodopa ther-
apy in PD patients with motor complications, suggests that
dopamine agonists may provide more eﬀective symptomatic
control [112].
5.3.1. Oﬀ-Time Reduction. There is no (or little) evidence of
ad i ﬀerence across the diﬀerent dopamine agonists for the
overallreductioninoﬀ-time[pramipexole(−1.81hours/day,
CI −2.19 to −1.43; P<0.00001); bromocriptine (−1.78
hours/day, CI −2.91 to −0.65; P = 0.002); pergolide (−1.60
hours/day, CI −2.57 to −0.63; P = 0.001); cabergoline
(−1.29hours/day,CI −1.89to −0.69;P<0.0001);ropinirole
(−0.93hours/day, CI −1.53 to −0.33; P = 0.002)] [112].
5.3.2. Levodopa Daily Dose Reduction. The largest reduction
was with pergolide (−183.90mg/day, CI −259.09 to −72.71;
P = 0.001), though this was based on data from just one trial
[71]. Cabergoline reduced the required levodopa dose by
149.60mg/day (CI −208.79 to −90.41; P<0.00001), ropini-
role by 119.81mg/day (CI −150.63 to −89.00; P<0.00001),
pramipexole by 114.82mg/day (CI −143.01 to −86.64; P<
0.00001), and bromocriptine by 52.17mg/day (CI −95.16 to
−9.18; P = 0.02) [112].
5.3.3. UPDRS Scores Improvement. The agonist pramipexole
appeared to produce larger improvements for UPDRS motor
score (−6.31 points, CI −7.69 to −4.93; P<0.00001) com-
pared to ropinirole (UPDRS motor: −4.80 points, CI −7.32
to −2.28; P = 0.0002) and cabergoline (UPDRS motor:
−1.74 points, CI −3.78 to 0.30; P = 0.09) [112].
5.3.4. Incidence of Dyskinesia. The analysis included 6476
participants, which represented 85% of the 7590 randomised
participants included in the meta-analysis. Compared to
placebo, the incidence of dyskinesia was increased with adju-
vant therapy. The incidence of dyskinesia was greatest with
pergolide (OR 4.64, CI 3.09 to 6.97; P<0.00001), although
the data were obtained from just one trial [71], followed by
ropinirole (OR 3.21, CI 1.98 to 5.21; P<0.00001), pram-
ipexole (OR 2.63, CI 2.01 to 3.42; P<0.00001), bromocrip-
tine (OR 2.52, CI 1.42 to 4.48; P = 0.002), and cabergoline
(OR 1.44, CI 0.96 to 2.16; P = 0.08) [112].
Though this meta-analysis indirectly compares several
series on dopaminergic agents as adjuvant treatment, the
need of large randomised studies that directly compare dif-
ferent agents administered as monotherapy with patient-
rated overall quality of life and health economic measures as
primary outcomes is recommended.
6.AlternativeTreatments toReduce Dyskinesia
As seen earlier, the primary therapeutic strategy for manag-
ing LIDs in PD patients is to delay their occurrence through
delaying the introduction of levodopa therapy administering
dopaminergic agents.
Once dyskinesias have occurred, other strategies should
be attempted: (1) substitution of immediate release for con-
trolled-release levodopa. The immediate-release preparation
is easier to adjust, as onset of its eﬀects is sooner, and dura-
tion of action (and dyskinesias) is shorter than with con-
trolled-release preparations. For the same reason, agents that
prolong the half-life of levodopa, such as entacapone, should
be stopped; (2) discontinuation of other therapy that may
embitter dyskinesias, as dopamine agonists or other factors
delaying dopamine degradation as selegiline and rasagiline;
(3) incrementation of the number of administrations of
levodopa, in lower doses; (4) addition of an antidyskinetic
agent as amantadine, an NMDA receptor antagonist. Dipha-
sic dyskinesias that may manifest at the beginning and the
end of a dosing cycle should be managed by utilising more
frequent doses of levodopa, and the therapy should be sewed
on the patient [113].
6.1. Amantadine. The NMDA receptor-binding and neuro-
toxic eﬀects of excessive glutamate have led to the hypothesis
that an NMDA antagonist may have antidyskinetic eﬀects
and reduce the severity of LIDs. Amantadine has been
studied as adjuvant treatment in levodopa-treated patients
experiencing motor complications, including dyskinesias,
with the aim of reducing these eﬀects without worsen-
ing Parkinsonian symptoms [114–117]. Three randomized
placebo-controlled crossover clinical studies in a group of 53
PD patients showed a reduction (up to 60%) in the severity
of LIDs after challenge with acute levodopa administration,
without impacting the beneﬁcial eﬀects of levodopa on
motor function.
6.2. Clozapine. It is an atypical antipsychotic that has been
assessed for the treatment of drug-induced psychosis in PD.8 Parkinson’s Disease
It may also be eﬀective in decreasing dyskinesias [70], and
a few studies have focused on its antidyskinetic eﬀect [118,
119].
6.3. Intraduodenal Levodopa. It provides direct delivery of
levodopa to the duodenum and jejunum. The method
involves insertion of a permanent access tube in the abdom-
inal wall by percutaneous endoscopic gastrostomy. Several
clinical studies have been conducted using this approach,
demonstrating signiﬁcant reductions in “oﬀ” time and dysk-
inesia after 6 months. It may be an option for patients with
marked ﬂuctuations and dyskinesia in whom deep-brain
stimulation (DBS) is contraindicated or not possible due to
advanced age, or it may provide an alternative to DBS.
6.4. Surgical Treatment. Patients with PD who may beneﬁt
from surgery include those who have substantial dyskine-
sias unresponsive to medication adjustments, are levodopa
responsive, do not have dementia, and do not have neu-
ropsychiatric impairment [80]. DBS is the most frequently
performedsurgeryforPDin NorthAmerica[80].Inpatients
with advanced PD, DBS of the globus pallidus interna (GPi)
or the subthalamic nucleus (STN) has been shown to reduce
dyskinesia severity by up to 89% [120,121] and to reduce the
duration of dyskinesias by 86% [122]. It provides signiﬁcant
improvement in Parkinsonian motor features and allows a
reduction of dyskinesias, in part through the subsequent
reduction of levodopa [123, 124].
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